Alimentary Pharmacology and Therapeutics
Long-term outcomes of thalidomide in refractory Crohn’s disease M. E. Gerich1, J. L. Yoon1, S. R. Targan, A. F. Ippoliti & E. A. Vasiliauskas
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Correspondence to: Dr J. L. Yoon, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, California, 90048, United States. E-mail: [email protected]
SUMMARY Background Several open-label and retrospective studies have indicated that thalidomide may be beneficial in patients with refractory Crohn’s disease (CD). Aim To report our long-term experience with the use of thalidomide for adults with refractory Crohn’s disease.
1
These authors contributed equally to this work.
Publication data Submitted 7 January 2014 First decision 22 January 2014 Resubmitted 22 July 2014 Resubmitted 25 November 2014 Accepted 27 November 2014 EV Pub Online 15 December 2014 This article was accepted for publication after full peer-review.
Methods We conducted a retrospective study of long-term clinical and safety outcomes among adults treated with thalidomide for refractory Crohn’s disease. Response was defined as a clinician’s assessment of improvement after at least 7 days treatment of one or more of the following: bowel movement frequency, fistula output, rectal bleeding, abdominal pain, extraintestinal manifestations, or well-being. Remission required all of the following:
Long-term outcomes of thalidomide in refractory Crohn’s disease M. E. Gerich1, J. L. Yoon1, S. R. Targan, A. F. Ippoliti & E. A. Vasiliauskas
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Correspondence to: Dr J. L. Yoon, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, California, 90048, United States. E-mail: [email protected]
SUMMARY Background Several open-label and retrospective studies have indicated that thalidomide may be beneficial in patients with refractory Crohn’s disease (CD). Aim To report our long-term experience with the use of thalidomide for adults with refractory Crohn’s disease.
1
These authors contributed equally to this work.
Publication data Submitted 7 January 2014 First decision 22 January 2014 Resubmitted 22 July 2014 Resubmitted 25 November 2014 Accepted 27 November 2014 EV Pub Online 15 December 2014 This article was accepted for publication after full peer-review.
Methods We conducted a retrospective study of long-term clinical and safety outcomes among adults treated with thalidomide for refractory Crohn’s disease. Response was defined as a clinician’s assessment of improvement after at least 7 days treatment of one or more of the following: bowel movement frequency, fistula output, rectal bleeding, abdominal pain, extraintestinal manifestations, or well-being. Remission required all of the following:
